Gold is 2025’s best performer. UBS sees more upside
On Friday, H.C. Wainwright analyst Emily Bodnar reaffirmed a Buy rating and a $15.00 price target for Femasys Inc. (NASDAQ:FEMY), which currently trades at $1.34. Bodnar provided insights into the company’s fourth quarter and full-year financials for 2024, as well as updates on corporate progress. Despite Femasys’ 2024 revenue falling short of expectations at $1.6 million, compared to the projected $2.1 million, the analyst remains optimistic about the company’s future performance. According to InvestingPro data, the company’s market cap stands at $30.57 million, with analysts anticipating sales growth in the current year despite recent challenges.
Femasys’ 2024 sales included $509,650 from FemaSeed following its market introduction that year. The company experienced a notable demand for FemaSeed in Spain. Additionally, FemVue, another product in the company’s portfolio, showed a 6.9% year-over-year sales growth while maintaining a consistent selling price. Diagnostic product sales were estimated at $0.32 million for the fourth quarter and $1.1 million for the entire year. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 3.94, though it’s currently burning through cash at a notable rate.
The revenue from FemaSeed remained relatively unchanged from the third to the fourth quarter of 2024. However, Bodnar noted that the full impact of marketing efforts in the United States had not been realized within the year. It is anticipated that these efforts will start to reflect in sales beginning in the first quarter of 2025. Femasys has been gradually increasing the availability of FemaSeed on a center-by-center basis.
HRC Facility, one of Femasys’ partners, has started to promote FemaSeed on its website, indicating a growing marketing initiative. Nevertheless, due to a slower-than-expected ramp-up in 2024, H.C. Wainwright has adjusted its 2025 revenue estimates for Femasys to $10 million, down from the previous $12.4 million forecast. Despite this adjustment, the firm maintains its Buy rating and $15 price target for Femasys stock.
In other recent news, Femasys Inc. has announced several key developments that are capturing the attention of investors. The company has received CE mark certification for its FemBloc delivery system, marking the first regulatory approval for this non-surgical contraceptive method under the European Union Medical (TASE:BLWV) Device Regulation. This certification allows Femasys to begin pre-marketing activities in Europe, with plans to launch in Spain, France, Italy, and Germany. Additionally, Femasys has gained UK regulatory approval for three of its products: the FemaSeed Intratubal Insemination device, FemVue for tubal evaluation, and FemCerv for cervical cancer detection.
In a separate development, H.C. Wainwright analyst Emily Bodnar raised the price target for Femasys shares to $15, up from $12, while maintaining a Buy rating. This adjustment follows Femasys’ partnership with CNY Fertility, which will offer the FemaSeed product across its network, expanding its availability to new states. Analysts at H.C. Wainwright project that FemaSeed could generate $1 million in revenue in 2024, with a significant increase to $11 million in 2025. The company is also progressing with its FDA-approved pivotal clinical trial for FemBloc in the United States. These recent developments underscore Femasys’ strategic expansion in both the European and UK markets, enhancing its portfolio of women’s health solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.